• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Protein binding of valproic acid in uremic patients.

作者信息

Bruni J, Wang L H, Marbury T C, Lee C S, Wilder B J

出版信息

Neurology. 1980 May;30(5):557-9. doi: 10.1212/wnl.30.5.557-a.

DOI:10.1212/wnl.30.5.557-a
PMID:6768007
Abstract

Protein binding of valproic acid was studied in four uremic patients on long-term hemodialysis. Before dialysis, the free fraction was 0.31 +/- 0.11 (SD); this was larger than in nonuremic subjects. During hemodialysis, the free fraction increased significantly (p less than 0.01) in three patients (mean, 0.64 +/- 0.32 SD).

摘要

相似文献

1
Protein binding of valproic acid in uremic patients.
Neurology. 1980 May;30(5):557-9. doi: 10.1212/wnl.30.5.557-a.
2
Diminished protein binding capacity of uremic sera for valproate following hemodialysis: role of free fatty acids and uremic compounds.血液透析后尿毒症血清与丙戊酸盐的蛋白结合能力降低：游离脂肪酸和尿毒症化合物的作用。
Am J Nephrol. 1996;16(4):327-33. doi: 10.1159/000169018.
3
Reduced in vitro displacement of valproic acid from protein binding by salicylate in uremic sera compared with normal sera. Role of uremic compounds.
Am J Clin Pathol. 1994 Mar;101(3):349-53.
4
Valproate plasma protein binding in the uremic condition.
Clin Pharmacol Ther. 1980 Jan;27(1):76-82. doi: 10.1038/clpt.1980.12.
5
Uremic sera contain inhibitors that block digitoxin-valproic acid interaction.
Am J Med Sci. 2001 Oct;322(4):204-8. doi: 10.1097/00000441-200110000-00010.
6
Displacement of valproic acid and carbamazepine from protein binding in normal and uremic sera by tolmetin, ibuprofen, and naproxen: presence of inhibitor in uremic serum that blocks valproic acid-naproxen interactions.托美汀、布洛芬和萘普生对正常血清及尿毒症血清中丙戊酸和卡马西平蛋白结合的置换作用：尿毒症血清中存在阻断丙戊酸 - 萘普生相互作用的抑制剂
Ther Drug Monit. 1996 Jun;18(3):284-7. doi: 10.1097/00007691-199606000-00011.
7
The effect of isohydric hemodialysis on the binding and removal of uremic retention solutes.等渗血液透析对尿毒症潴留溶质结合及清除的影响。
PLoS One. 2018 Feb 22;13(2):e0192770. doi: 10.1371/journal.pone.0192770. eCollection 2018.
8
Cortisol binding in uremic plasma. II. Decreased cortisol binding to albumin.尿毒症血浆中的皮质醇结合。II. 皮质醇与白蛋白的结合减少。
Nephron. 1984;37(4):229-31. doi: 10.1159/000183254.
9
Influence of chronic renal failure and hemodialysis on diflunisal plasma protein binding.慢性肾衰竭和血液透析对双氟尼酸血浆蛋白结合的影响。
Clin Pharmacol Ther. 1980 May;27(5):628-35. doi: 10.1038/clpt.1980.89.
10
Exploring Protein Binding of Uremic Toxins in Patients with Different Stages of Chronic Kidney Disease and during Hemodialysis.探索不同阶段慢性肾脏病患者及血液透析期间尿毒症毒素的蛋白结合情况。
Toxins (Basel). 2015 Sep 28;7(10):3933-46. doi: 10.3390/toxins7103933.

引用本文的文献

1
Renal transplant recipient seizure practical management.肾移植受者癫痫的实际管理
World J Nephrol. 2020 Jun 30;9(1):1-8. doi: 10.5527/wjn.v9.i1.1.
2
Pharmacokinetic of antiepileptic drugs in patients with hepatic or renal impairment.肝或肾功能损害患者的抗癫痫药物药代动力学。
Clin Pharmacokinet. 2014 Jan;53(1):29-49. doi: 10.1007/s40262-013-0107-0.
3
Decreased plasma protein binding of valproate in patients with acute head trauma.急性颅脑外伤患者丙戊酸盐的血浆蛋白结合率降低。
Br J Clin Pharmacol. 1994 Jun;37(6):559-62. doi: 10.1111/j.1365-2125.1994.tb04304.x.
4
Intra-dose variation in plasma protein binding of sodium valproate in epileptic patients.癫痫患者中丙戊酸钠血浆蛋白结合的剂量内变异
Br J Clin Pharmacol. 1982 Sep;14(3):399-404. doi: 10.1111/j.1365-2125.1982.tb01998.x.
5
Alteration of drug-protein binding in renal disease.肾脏疾病中药物与蛋白质结合的改变。
Clin Pharmacokinet. 1984 Jan;9 Suppl 1:18-26. doi: 10.2165/00003088-198400091-00003.
6
Free level monitoring of antiepileptic drugs. Clinical usefulness and case studies.抗癫痫药物的游离水平监测。临床实用性及病例研究。
Clin Pharmacokinet. 1984 Jan;9 Suppl 1:71-8. doi: 10.2165/00003088-198400091-00009.
7
Drug therapy in patients undergoing haemodialysis. Clinical pharmacokinetic considerations.接受血液透析患者的药物治疗。临床药代动力学考量
Clin Pharmacokinet. 1984 Jan-Feb;9(1):42-66. doi: 10.2165/00003088-198409010-00003.
8
Distribution of sodium valproate in normal whole blood and in blood from patients with renal or hepatic disease.
Eur J Clin Pharmacol. 1985;28(4):447-52. doi: 10.1007/BF00544365.
9
Free drug concentration monitoring in clinical practice. Rationale and current status.临床实践中的游离药物浓度监测。原理与现状。
Clin Pharmacokinet. 1986 Nov-Dec;11(6):450-69. doi: 10.2165/00003088-198611060-00003.
10
Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).疾病引起的血浆蛋白水平变化。对药物给药方案的影响（第二部分）。
Clin Pharmacokinet. 1990 Sep;19(3):218-29. doi: 10.2165/00003088-199019030-00005.